Crowd tape
Reddit crowd sentimentTracked across the finance subredditsSee the dashboard for live mention data

Hedge fund · Long-only 13F filer

Baker Bros. Advisors

$20.0B+$2.5B vs prior 13FUS long stock positions · not assets under managementSEC EDGAR · 13F-HR · filed 14 August 2026

Baker Bros. Advisors's latest 13F filing covers the quarter ended 30 June 2026 and was filed 14 August 2026 (45 days after quarter end): 83 disclosed US-listed positions — $20.0 billion in long stock. Eight new buys, five adds, three trims and nine exits against the prior quarter. Holdings are up to 45 days old by the time they clear EDGAR.

Portfolio · vs S&P 500Baker Bros. AdvisorsS&P 500
Sept 2025Baker Bros. Advisors +44% · S&P: +12%

The line rebuilds Baker Bros. Advisors's disclosed 13F holdings at each filing and holds them to the next, tracked against the S&P 500 where daily price history overlaps. Long US equity only — an illustrative read, not an audited return.

S&P 500 overlay: Finazon · prior-day close, most closes dollar-rounded at the source

Portfolio · vs S&P 500Baker Bros. AdvisorsS&P 500
Sept 2024Baker Bros. Advisors +106% · S&P from Sept 2025: +12%

The line rebuilds Baker Bros. Advisors's disclosed 13F holdings at each filing and holds them to the next, tracked against the S&P 500 where daily price history overlaps. Long US equity only — an illustrative read, not an audited return.

S&P 500 overlay: Finazon · prior-day close, most closes dollar-rounded at the source

Long stock value$20.0B
Positions83
Top holdingINCY · 17.5%
Top sectorHealthcare 81%
New buys · Q2 20268
Exits · Q2 20269

Portfolio reconstructed from SEC EDGAR 13F filings · values as reported · as of Q2 2026

Top holdings — quarter ended 30 June 2026

Largest 15 of 83 positions
PositionValueWeightSharesLast quarter
INCYIncyte Corporation$3.5B17.5%30.8MHeld
ONCBeOne Medicines Ltd.$2.5B12.6%8.8MHeld
RVMDRevolution Medicines, Inc.$2.1B10.7%11.4MHeld
MDGLMadrigal Pharmaceuticals, Inc.$1.2B5.8%2.1MHeld
ACADACADIA Pharmaceuticals Inc.$1.1B5.4%42.9MHeld
KYMRKymera Therapeutics, Inc.$992.7M5.0%8.7MHeld
INSMInsmed Incorporated$937.8M4.7%8.8MHeld
CELCCelcuity Inc.$828.2M4.2%7.9MHeld
KODKodiak Sciences Inc.$776.1M3.9%19.9MHeld
RYTMRhythm Pharmaceuticals, Inc.$622.3M3.1%5.6MHeld
PRAXPraxis Precision Medicines, Inc.$587.0M2.9%1.8MHeld
ALKSAlkermes plc$524.6M2.6%10.0MHeld
SMMTSummit Therapeutics Inc.$477.7M2.4%32.8MHeld
GRALGRAIL, Inc.$275.0M1.4%4.0MHeld
ABCLAbCellera Biologics Inc.$259.1M1.3%33.0MHeld

Quarterly changes — quarter ended 30 June 2026

25 changes vs prior quarter
New buys8
Adds5
Trims3
Exits9

What changed against the previous quarter's filing: new positions first, then adds, trims and exits, each sorted by position size.

PositionChangeShares movedValue after
SNSEFaeth Therapeutics, Inc.New buy+1.3M$32.2M
CYTKCytokinetics, IncorporatedNew buy+211.3K$18.0M
NTLAIntellia Therapeutics, Inc.New buy+930.2K$15.7M
Parabilis Medicines, Inc.New buy+500.0K$13.7M
Avalyn Pharma Inc.New buy+350.0K$11.5M
TNGXTango Therapeutics, Inc.New buy+333.3K$10.4M
AVTXAvalo Therapeutics, Inc.New buy+550.0K$10.2M
IMNMImmunome, Inc.New buy+55.3K$1.2M
IDYAIDEAYA Biosciences, Inc.Added+1.1M$186.7M
RLAYRelay Therapeutics, Inc.Added+1.7M$52.9M
CLDXCelldex Therapeutics, Inc.Added+517.2K$44.0M
RCUSArcus Biosciences, Inc.Added+429.2K$26.0M
VSTMVerastem, Inc.Added+1.9M$9.5M
EWTXEdgewise Therapeutics, Inc.Trimmed−2.9M$150.4M
JBIOJade Biosciences, Inc.Trimmed−410.7K$27.3M
CERSCerus CorporationTrimmed−3.6M$18.7M
ABVXAbivax S.A.Sold out−875.8Kwas $97.5M
Celcuity Inc.Sold out−30.8Mwas $74.9M
SYRESpyre Therapeutics, Inc.Sold out−1.0Mwas $50.4M
CNTACentessa Pharmaceuticals plcSold out−670.8Kwas $26.6M
IMCRImmunocore Holdings plcSold out−734.4Kwas $22.1M
CTNMContineum Therapeutics, Inc.Sold out−1.4Mwas $18.6M
ARGXargenx SESold out−25.2Kwas $18.4M
CMPSCOMPASS Pathways plcSold out−2.3Mwas $13.0M
PHVSPharvaris N.V.Sold out−375.0Kwas $10.6M

Sector allocation

Healthcare81%
Other / unclassified19%
Technology0%

Holdings by sector

Healthcare carries the largest share of disclosed value, at 81%.

Healthcare81%
ABSI · ACAD · ALKS · ALMS · ARWR · BNTX · CELC · CERS · CLDX · CRNX · CTMX · CYTK · DBVT · DNLI · DSGN · DYN · ELVN · GLUE · GPCR · IDYA · IMNM · IMVT · INCY · INSM · IONS · IRON · KNSA · KOD · KYMR · MDGL · MIRM · NGNE · NRIX · NTLA · PRAX · PRLD · RAPP · RCUS · REPL · RLAY · RVMD · RYTM · SANA · SERA · SGMT · SKYE · SMMT · STOK · TARA · TCRX · TECX · TNGX · TRDA · TSHA · TYRA · VRDN · VSTM · VTVT · WVE · XENE · XNCR
Other / unclassified19%
ABCL · ALGS · AVTX · BCYC · EIKN · EVMN · EWTX · GRAL · IMTX · JBIO · LBRX · MPLT · ONC · ROIV · SION · SNSE · SRZNW
Technology0%
AKTS
What is Baker Bros. Advisors's biggest holding?

As of the quarter ended 30 June 2026, the largest disclosed position was INCY (Incyte Corporation), about 17.5% of the disclosed US-listed portfolio by reported value.

What did Julian & Felix Baker's Baker Bros. Advisors buy in Q2 2026?

8 new positions were disclosed for the quarter ended 30 June 2026; the largest were SNSE, CYTK, NTLA. Adds and trims are listed in the quarterly-changes table on this page.

How concentrated is the portfolio?

Fairly concentrated. The top five positions are 52% of disclosed value and the top ten are 73%.

When is Baker Bros. Advisors's next 13F due?

13F filings for the quarter ended 30 September 2026 are due by 16 November 2026 — managers have 45 days after each calendar quarter ends. Whether Baker Bros. Advisors files is up to the manager; we show whatever EDGAR receives.

Does this show the whole portfolio?

No. Form 13F covers US-listed long equity and some options only — no short bets, bonds, cash, private businesses, non-US holdings or timing inside the quarter. Amended filings replace originals; this page always shows the latest canonical version.

Read the form itself on SEC EDGAR or see our plain-words guide to 13F filings — Baker Bros. Advisors may have already changed these positions since 30 June 2026.

Baker Bros. Advisors 13F portfolio — holdings and quarterly moves · The Distributed